Related Experiment Video
Updated: Jun 22, 2025
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.1K
Cardio-oncology in advanced prostate cancer
Kenneth Chen1,2, Ting Hong Wong3, Yu Guang Tan1
1Department of Urology, Singapore General Hospital, Singapore, Singapore.
Frontiers in Oncology
|July 1, 2024
Summary
Advanced prostate cancer treatments like androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPi) improve survival but pose cardiovascular risks. Optimizing cardiovascular health is crucial for patients undergoing these therapies.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- Advanced prostate cancer treatments, including androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPi), improve patient survival.
- Both ADT and ARPi are associated with significant cardiovascular toxicity, exacerbating risks in a population with pre-existing cardiovascular risk factors.
- There is a critical need to address and manage the cardiovascular health of prostate cancer survivors undergoing hormonal manipulation.
Purpose of the Study:
- To review the cardiovascular impact of hormonal therapies in metastatic hormone-sensitive prostate cancer.
- To propose strategies for mitigating cardiovascular toxicity associated with ADT and ARPi.
- To raise awareness of the cardiovascular effects of current prostate cancer hormonal management.
Main Methods:
- Literature review of cardiovascular toxicity associated with ADT and ARPi in prostate cancer.
- Discussion of cardiovascular risk assessment tools (e.g., SCORE2).
- Exploration of treatment de-escalation strategies and the role of biomarkers (e.g., AR-V7) in personalized therapy.
Main Results:
- No specific calculators for ADT/ARPi cardiovascular toxicity exist; general tools like SCORE2 can be utilized.
- Selected patients may benefit from de-escalated ADT if they show exceptional PSA response, have favorable disease characteristics, and significant comorbidities.
- Biomarkers like AR-V7 may identify patients suitable for de-escalated treatment, while optimizing modifiable cardiovascular risk factors (ABCDE framework, exercise) is essential.
Conclusions:
- Managing cardiovascular health is paramount in advanced prostate cancer patients receiving hormonal therapies.
- Personalized treatment de-escalation and risk factor optimization are key strategies to mitigate cardiovascular toxicity.
- Further research and awareness are needed regarding the cardiovascular implications of prostate cancer hormonal treatments.
Keywords:
abirateroneadvanced prostate cancerandrogen deprivation therapyandrogen receptor pathway inhibitorscardio-oncologycardiovascular healthenzalutamidemetastatic prostate cancerMore Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
01:21Cancer Survival Analysis
342
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
152
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
152
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K